-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Professor Wang Jianxiang from the Hospital of Hematology of the Chinese Academy of Medical Sciences congratulated Daratumumab injection (generic name in English: daratumumab) on the approval of the new indication of Daratumumab in China.
The combination of lenalidomide and dexamethasone (Dara-Rd) or the combination of bortezomib and dexamethasone (Dara-Vd) in the treatment of adult patients with multiple myeloma who have received at least first-line treatment in the past.
The approval of this new indication will further fill the gap in the treatment of relapsed or refractory multiple myeloma in my country, and bring more innovative options to patients who are at an earlier stage of treatment for first relapse.
As we all know, multiple myeloma (MM) is progressive, recurring and difficult to cure.
Almost all patients with MM experience one or more recurrences throughout the course of the disease.
This is the natural course of the disease1 and is also the treatment of myeloma.
difficulty.
For the treatment of relapsed/refractory MM, the "Guidelines for the Diagnosis and Treatment of Multiple Myeloma in China (Revised in 2020)" clearly stated that the goal of the first relapse treatment is to obtain the greatest degree of remission and prolong progression-free survival.
Multi-line recurrence treatment and goals are to improve the quality of life of patients as the main treatment goal, and on this basis, to achieve the greatest possible remission2.
Development of treatment strategies for first/multi-line relapse MM.
The current treatment plan, which is based on proteasome inhibitors and immunomodulators, has limited remission depth and survival benefits for patients with relapse and refractory disease, with low complete remission rate and progression-free survival The period is less than 1 year3, and there is an urgent need for new treatment mechanisms to improve the survival outcome of patients with relapsed MM.Daratumumab is the first CD38 monoclonal antibody marketed in China.
Daratumumab is the first CD38 monoclonal antibody marketed in China4.
It has a unique dual immune mechanism that directly kills myeloma cells and activates immunity.
5,6, the newly approved combination treatment plan DRd/DVd in China for the treatment of relapsed/refractory MM, the depth of remission and survival benefit are significantly better, especially for patients with first relapse 7-10.
The second-line indications of daratumumab DRd/DVd are officially approved in China.
Currently, the latest NCCN guidelines 11, ESMO guidelines 12, and China MM diagnosis and treatment guidelines (revised in 2020) 2 all recommend daratumumab-based The combined treatment plan DVd/DRd is one of the recommended treatment plans for relapsed/refractory myeloma to help patients with myeloma have a deeper remission and longer survival.References: 1.
J Adv Pract Oncol 2013;4(Suppl 1):5-14.
2.
Chinese Medical Doctor Association Hematologist Branch, Chinese Medical Association Hematology Branch, Chinese Medical Doctor Association Multiple Myeloma Professional Committee.
China Multiple Bone Marrow Tumor diagnosis and treatment guidelines (revised in 2020)[J].
Chinese Journal of Internal Medicine 2020,59(5):341-346.
3.
Jagannath S et al.
Expert Rev Hematol.
2016 Jul;9(7):707-17.
4.
Multiple bone marrow Tumor treatment drug daratumomab injection was approved for marketing.
2019-07-05.
5.
Sanchez L, et al .
J Hematol Oncol.
2016 Jun 30;9(1):51.
6.
Mckeage K ,et al.
Drugs & Therapy Perspectives, 2016, 32(11):463-469.
7.
Mateos MV, Sonneveld P, Hungria V, et al.
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR.
Clin Lymphoma Myeloma Leuk.
2020 Aug;20(8):509-518.
8.
Weisel K, et al, ASH 2019, poster 3192.
9.
Bahlis NJ, Dimopoulos MA, White DJ, et al.
Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study.
Leukemia.
2020 Jul;34(7):1875-1884.
10.
Kaufman JL, et al, ASH 2019, poster 1866.
11.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Multiple Myeloma.
2021.
V3.
12.
Dimopoulos MA, Moreau P, Terpos E, et al.
Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up.
Hemasphere.
2021 Feb 3;5(2):e528.
Stamp "read the original text", we make progress togetherMultiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up.
Hemasphere.
2021 Feb 3;5(2):e528.
Stamp "Read the original text", we make progress togetherMultiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up.
Hemasphere.
2021 Feb 3;5(2):e528.
Stamp "Read the original text", we make progress together
The combination of lenalidomide and dexamethasone (Dara-Rd) or the combination of bortezomib and dexamethasone (Dara-Vd) in the treatment of adult patients with multiple myeloma who have received at least first-line treatment in the past.
The approval of this new indication will further fill the gap in the treatment of relapsed or refractory multiple myeloma in my country, and bring more innovative options to patients who are at an earlier stage of treatment for first relapse.
As we all know, multiple myeloma (MM) is progressive, recurring and difficult to cure.
Almost all patients with MM experience one or more recurrences throughout the course of the disease.
This is the natural course of the disease1 and is also the treatment of myeloma.
difficulty.
For the treatment of relapsed/refractory MM, the "Guidelines for the Diagnosis and Treatment of Multiple Myeloma in China (Revised in 2020)" clearly stated that the goal of the first relapse treatment is to obtain the greatest degree of remission and prolong progression-free survival.
Multi-line recurrence treatment and goals are to improve the quality of life of patients as the main treatment goal, and on this basis, to achieve the greatest possible remission2.
Development of treatment strategies for first/multi-line relapse MM.
The current treatment plan, which is based on proteasome inhibitors and immunomodulators, has limited remission depth and survival benefits for patients with relapse and refractory disease, with low complete remission rate and progression-free survival The period is less than 1 year3, and there is an urgent need for new treatment mechanisms to improve the survival outcome of patients with relapsed MM.Daratumumab is the first CD38 monoclonal antibody marketed in China.
Daratumumab is the first CD38 monoclonal antibody marketed in China4.
It has a unique dual immune mechanism that directly kills myeloma cells and activates immunity.
5,6, the newly approved combination treatment plan DRd/DVd in China for the treatment of relapsed/refractory MM, the depth of remission and survival benefit are significantly better, especially for patients with first relapse 7-10.
The second-line indications of daratumumab DRd/DVd are officially approved in China.
Currently, the latest NCCN guidelines 11, ESMO guidelines 12, and China MM diagnosis and treatment guidelines (revised in 2020) 2 all recommend daratumumab-based The combined treatment plan DVd/DRd is one of the recommended treatment plans for relapsed/refractory myeloma to help patients with myeloma have a deeper remission and longer survival.References: 1.
J Adv Pract Oncol 2013;4(Suppl 1):5-14.
2.
Chinese Medical Doctor Association Hematologist Branch, Chinese Medical Association Hematology Branch, Chinese Medical Doctor Association Multiple Myeloma Professional Committee.
China Multiple Bone Marrow Tumor diagnosis and treatment guidelines (revised in 2020)[J].
Chinese Journal of Internal Medicine 2020,59(5):341-346.
3.
Jagannath S et al.
Expert Rev Hematol.
2016 Jul;9(7):707-17.
4.
Multiple bone marrow Tumor treatment drug daratumomab injection was approved for marketing.
2019-07-05.
5.
Sanchez L, et al .
J Hematol Oncol.
2016 Jun 30;9(1):51.
6.
Mckeage K ,et al.
Drugs & Therapy Perspectives, 2016, 32(11):463-469.
7.
Mateos MV, Sonneveld P, Hungria V, et al.
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR.
Clin Lymphoma Myeloma Leuk.
2020 Aug;20(8):509-518.
8.
Weisel K, et al, ASH 2019, poster 3192.
9.
Bahlis NJ, Dimopoulos MA, White DJ, et al.
Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study.
Leukemia.
2020 Jul;34(7):1875-1884.
10.
Kaufman JL, et al, ASH 2019, poster 1866.
11.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Multiple Myeloma.
2021.
V3.
12.
Dimopoulos MA, Moreau P, Terpos E, et al.
Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up.
Hemasphere.
2021 Feb 3;5(2):e528.
Stamp "read the original text", we make progress togetherMultiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up.
Hemasphere.
2021 Feb 3;5(2):e528.
Stamp "Read the original text", we make progress togetherMultiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up.
Hemasphere.
2021 Feb 3;5(2):e528.
Stamp "Read the original text", we make progress together
